Bernard Lo, M.D., president of the Greenwall Foundation and director emeritus of the Program in Medical Ethics at the University of California, San Francisco, will deliver the next Flexner Discovery Lecture on Thursday, Sept. 25.

Vanderbilt University researchers have partnered with Mapp Biopharmaceutical Inc. to develop new human antibody therapies for people exposed to the deadly Ebola and Marburg viruses.

Vanderbilt Heart and Vascular Institute is participating in a global clinical trial to test the safety and efficacy of the world’s smallest pacemaker.

Exposure of male mice to the pollutant dioxin causes preterm birth across multiple generations, suggesting that efforts to prevent preterm birth should include pre-conception interventions for dads.

Stem cells derived from patients with pulmonary arterial hypertension provide a unique resource for studying the molecular defects that cause the disease and testing potential therapies.

Drugs developed at Vanderbilt could provide a new way to treat schizophrenia in a personalized way.

A combination treatment delivered to the site of fractures may improve bone healing in patients with the genetic disease neurofibromatosis type-1.